The estimated Net Worth of Douglas Matthew Brown is at least $4.56 Milion dollars as of 23 November 2021. Mr Brown owns over 100,000 units of Neogenomics stock worth over $189,914 and over the last 4 years he sold NEO stock worth over $3,696,000. In addition, he makes $677,654 as Chief Strategy & Corp. Devel. Officer at Neogenomics.
Mr has made over 1 trades of the Neogenomics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 100,000 units of NEO stock worth $3,696,000 on 23 November 2021.
The largest trade he's ever made was selling 100,000 units of Neogenomics stock on 23 November 2021 worth over $3,696,000. On average, Mr trades about 20,000 units every 0 days since 2021. As of 23 November 2021 he still owns at least 11,644 units of Neogenomics stock.
You can see the complete history of Mr Brown stock trades at the bottom of the page.
Douglas M. Brown is the Chief Strategy & Corp. Devel. Officer at Neogenomics.
As the Chief Strategy & Corp. Devel. Officer of Neogenomics, the total compensation of Mr Brown at Neogenomics is $677,654. There are 5 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Mr Brown is 51, he's been the Chief Strategy & Corp. Devel. Officer of Neogenomics since . There are 17 older and 8 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Douglas's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van oraz Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: